OGX-011 is a second-generation antisense
drug designed to specifically inhibit the production of clusterin, a cell-survival protein that is up-regulated in response to standard anti-cancer treatments.
The resulting antisense
compounds shut down the cellular factory churning out a disease-causing protein.
announced today a cross-license agreement for the development of antisense
drugs targeting p53, a well-studied human protein that controls cellular response to genetic damage.
Therapeutics Limited, Melbourne, Australia will conduct a "proof of concept" study of ATL1101 in patients with psoriasis.
molecules are tiny pieces of DNA or RNA designed to bind to a cell's own DNA or RNA and interfere with its activity.
The contract will fund AVI's development of antisense
therapeutics to treat the effects of Ebola, Marburg and Junin hemorrhagic viruses, which are seen as biological warfare and bioterrorism agents.
covering broad applications in the field of nucleic acid technology and the second in Canada for antisense
RNA (genetic antisense
One approach involves small pieces of synthetic DNA, called antisense
(SN: 6/10/89, p.
drugs targeting hepatitis C virus, West Nile virus, and the oncogene c-myc found in the CSF after systemic administration to humans
Using a technique called antisense
genetics, Calgene researchers permanently endowed their tomato with a backward (antisense
) copy of the gene for polygalacturonase (PG), a fruit-softening enzyme.
Nasdaq:AVII), today announced publication of preclinical results from studies carried out by an international team of researchers showing the ability of NEUGENE([R]) antisense
to inhibit multiple strains of influenza A virus.
Using a new genetic technology called antisense
, researchers have completely shut down the operation of a gene that can cause the walls of arteries to thicken, reducing blood flow to a trickle.